Kezar Life Sciences (KZR) Net Income towards Common Stockholders (2021 - 2025)

Historic Net Income towards Common Stockholders for Kezar Life Sciences (KZR) over the last 5 years, with Q2 2025 value amounting to -$13.7 million.

  • Kezar Life Sciences' Net Income towards Common Stockholders rose 3639.95% to -$13.7 million in Q2 2025 from the same period last year, while for Sep 2025 it was -$50.5 million, marking a year-over-year increase of 4729.69%. This contributed to the annual value of -$83.7 million for FY2024, which is 1780.11% up from last year.
  • Latest data reveals that Kezar Life Sciences reported Net Income towards Common Stockholders of -$13.7 million as of Q2 2025, which was up 3639.95% from -$16.6 million recorded in Q1 2025.
  • In the past 5 years, Kezar Life Sciences' Net Income towards Common Stockholders ranged from a high of -$13.0 million in Q2 2021 and a low of -$32.3 million during Q4 2023
  • In the last 5 years, Kezar Life Sciences' Net Income towards Common Stockholders had a median value of -$18.2 million in 2022 and averaged -$19.2 million.
  • In the last 5 years, Kezar Life Sciences' Net Income towards Common Stockholders crashed by 7743.8% in 2023 and then surged by 3732.8% in 2024.
  • Over the past 5 years, Kezar Life Sciences' Net Income towards Common Stockholders (Quarter) stood at -$14.2 million in 2021, then fell by 27.93% to -$18.2 million in 2022, then plummeted by 77.44% to -$32.3 million in 2023, then soared by 37.33% to -$20.2 million in 2024, then skyrocketed by 32.22% to -$13.7 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$13.7 million for Q2 2025, versus -$16.6 million for Q1 2025 and -$20.2 million for Q4 2024.